Evaluation of the Prognostic Impact of Decreased Serum beta2 Microglobulin in the First Year of Follow-up of Myeloproliferative Neoplasia (PRODIGE)

N/AActive Not RecruitingNCT06553638

University Hospital, Brest50 enrolled

Overview

50 patients with a diagnosis of MPN will have an assessment of b2microglobuline at diagnosis and after 1 year. b2mic value decrease will be compared to treatment response.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Myeloproliferative Neoplasm

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * MPN patient diagnosed at one of the participating centers * over 18 yo Exclusion Criteria: * Not able to consent

Locations (1)

Chu Brest

Brest, France

Outcomes

Primary Outcomes

b2mic decrease level between responders and non-responders

Time frame: 1 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.